Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.60% | -8.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.60% | -8.90% | |||
| Cost of Revenue | 28.91% | -3.21% | |||
| Gross Profit | -45.00% | 1.12% | |||
| SG&A Expenses | 19.49% | 5.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.44% | -0.28% | |||
| Operating Income | -33.80% | -1.55% | |||
| Income Before Tax | -37.06% | 6.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.06% | 6.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.06% | 6.86% | |||
| EBIT | -33.80% | -1.55% | |||
| EBITDA | -34.36% | -1.31% | |||
| EPS Basic | -36.34% | 23.16% | |||
| Normalized Basic EPS | -36.37% | 23.19% | |||
| EPS Diluted | -37.93% | 23.68% | |||
| Normalized Diluted EPS | -36.37% | 23.19% | |||
| Average Basic Shares Outstanding | 0.53% | 21.21% | |||
| Average Diluted Shares Outstanding | 0.53% | 21.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||